FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Am J Vet Res / Pharmacokinetic-pharmacodynamic relationships and dose respo...
American journal of veterinary research2004; 65(11); 1533-1541; doi: 10.2460/ajvr.2004.65.1533

Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint.

Abstract: To determine pharmacokinetic-pharmacodynamic (PK-PD) relationships and dose effects for meloxicam in horses and to propose a suitable dosage for use in clinical studies. Methods: 6 adult horses. Methods: The study was conducted by use of a randomized, Latin-square design. Arthritis was induced in the right carpal joint of each horse by administration of Freund's complete adjuvant. Various dosages of meloxicam (0, 0.25, 0.5, 1.0, and 2.0 mg/kg, IV) were then administered. Validated endpoints including stride length and overall clinical lameness score (scale of 0 to 20) were used to assess the effect of meloxicam. The dose-effect relationship was quantified by use of a maximum possible effect (Emax) model. Results: For stride length (expressed as a relative percentage increase from control values), the median effective dose (ED50) was 0.120 mg/kg for an Emax of 11.15%. For clinical lameness score (expressed as an absolute increase from the control value), the ED50 was 0.265 mg/kg for an Emax of 9.16 units. The PK-PD analysis allowed calculation of a median effective concentration of 130 ng/mL for stride length and 195 ng/mL for lameness score. Use of the Emax model predicted a maximal possible increase in effect of 19.5% for stride length and 13.91 units for lameness score. For stride length and lameness score, the Hill coefficient (slope) was extremely high, which suggested a steep dose-effect relationship. Conclusions: Results of this study suggest that meloxicam is a potent anti-inflammatory drug in horses. A dosage of 0.6 mg/kg/d would be appropriate for use in a clinical study.
Get Full Text
Publication Date: 2004-11-30 PubMed ID: 15566092DOI: 10.2460/ajvr.2004.65.1533Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a study conducted to ascertain the relationship between pharmacokinetics, pharmacodynamics, and dosage effects of meloxicam medication in horses. Specifically, it sought to identify an appropriate dosage for use in clinical studies.

Research Methodology

  • The researchers used six adult horses for the study, following a randomized, Latin-square design.
  • They induced arthritis in the horses’ right carpal joint using Freund’s complete adjuvant.
  • Various doses of meloxicam (0, 0.25, 0.5, 1.0, and 2.0 mg/kg, IV) were then administered to the horses.
  • The effect of meloxicam was assessed using two validated endpoints: stride length and overall clinical lameness score (scale of 0 to 20).
  • The researchers utilized a maximum possible effect (Emax) model to quantify the dose-effect relationship.

Research Findings

  • The median effective dose (ED50) for stride length was 0.120 mg/kg for an Emax of 11.15%. Meanwhile, for the clinical lameness score, the ED50 was determined as 0.265 mg/kg for an Emax of 9.16 units.
  • The researchers conducted a PK-PD analysis, allowing them to compute the median effective concentration of 130 ng/mL for stride length and 195 ng/mL for lameness score.
  • The Emax model predicted that the maximum possible improvement could reach 19.5% for stride length and 13.91 units for lameness score.
  • The investigation found that meloxicam had a high Hill coefficient (slope) for both stride length and lameness score, indicating a steep dose-effect relationship.

Conclusions

  • The researchers concluded that meloxicam is a potent anti-inflammatory drug for horses.
  • Based on the study’s results, they suggest a dosage of 0.6 mg/kg/d would be suitable for use in future clinical studies.

Cite This Article

APA
Toutain PL, Cester CC. (2004). Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint. Am J Vet Res, 65(11), 1533-1541. https://doi.org/10.2460/ajvr.2004.65.1533

Publication

American journal of veterinary research
ISSN: 0002-9645
NlmUniqueID: 0375011
Country: United States
Language: English
Volume: 65
Issue: 11
Pages: 1533-1541

Researcher Affiliations

Toutain, Pierre-Louis
  • UMR 181 Physiopathologie et Toxicologie Experimentales, INRA/ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, 31076 Toulouse, France.
Cester, Corinne C

    MeSH Terms

    • Animals
    • Arthritis, Experimental / drug therapy
    • Arthritis, Experimental / veterinary
    • Biomechanical Phenomena
    • Chromatography, High Pressure Liquid
    • Dose-Response Relationship, Drug
    • Endpoint Determination / veterinary
    • Horse Diseases / metabolism
    • Horses
    • Lameness, Animal / metabolism
    • Meloxicam
    • Models, Biological
    • Thiazines / blood
    • Thiazines / pharmacokinetics
    • Thiazines / therapeutic use
    • Thiazoles / blood
    • Thiazoles / pharmacokinetics
    • Thiazoles / therapeutic use

    Citations

    This article has been cited 23 times.
    1. Chen JC, Yang F, Duan MH, Li ZE, Dai Y, Zhang M, Yang F. Pharmacokinetics of meloxicam in pigeons after single intravenous, oral, and intramuscular administration.. Poult Sci 2023 Sep;102(9):102869.
      doi: 10.1016/j.psj.2023.102869pubmed: 37390554google scholar: lookup
    2. Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses.. Animals (Basel) 2023 May 10;13(10).
      doi: 10.3390/ani13101597pubmed: 37238029google scholar: lookup
    3. Sarvi JY, Gardhouse SM, Kleinhenz MD, Hocker SE, Weeder MM, Montgomery SR, Rooney TA. Measurement of Cyclooxygenase Products in Plasma as Markers for Inhibition of Cyclooxygenase Isoforms by Oral Meloxicam in New Zealand White Rabbits (Oryctolagus cuniculus ).. J Am Assoc Lab Anim Sci 2023 May 1;62(3):254-259.
      doi: 10.30802/AALAS-JAALAS-22-000109pubmed: 37045554google scholar: lookup
    4. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.. Vet Anim Sci 2023 Mar;19:100286.
      doi: 10.1016/j.vas.2023.100286pubmed: 36684818google scholar: lookup
    5. Morón-Elorza P, Cañizares-Cooz D, Rojo-Solis C, Álvaro-Álvarez T, Valls-Torres M, García-Párraga D, Encinas T. Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (Raja undulata).. Vet Sci 2022 Apr 28;9(5).
      doi: 10.3390/vetsci9050216pubmed: 35622744google scholar: lookup
    6. Morón-Elorza P, Rojo-Solís C, Álvaro-Álvarez T, Valls-Torres M, García-Párraga D, Encinas T. Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nusehound Sharks (Scyliorhinus stellaris).. Front Vet Sci 2022;9:845555.
      doi: 10.3389/fvets.2022.845555pubmed: 35411304google scholar: lookup
    7. Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. Non-steroidal anti-inflammatory drugs in equine orthopaedics.. Equine Vet J 2022 Jan 25;54(4):636-48.
      doi: 10.1111/evj.13561pubmed: 35076950google scholar: lookup
    8. Norton TM, Clauss T, Overmeyer R, Stowell S, Kaylor M, Cox S. Multi-Injection Pharmacokinetics of Meloxicam in Kemp's Ridley (Lepidochelys kempii) and Green (Chelonia mydas) Sea Turtles after Subcutaneous Administration.. Animals (Basel) 2021 Dec 10;11(12).
      doi: 10.3390/ani11123522pubmed: 34944296google scholar: lookup
    9. Depenbrock S, Urbano T, Ziegler J, Wetzlich S, Clapham MO, Tell LA. Pharmacokinetic Parameters and Tissue Withdrawal Intervals for Sheep Administered Multiple Oral Doses of Meloxicam.. Animals (Basel) 2021 Sep 25;11(10).
      doi: 10.3390/ani11102797pubmed: 34679818google scholar: lookup
    10. Shock D, Roche S, Olson M. A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows.. Vet Sci 2019 Sep 5;6(3).
      doi: 10.3390/vetsci6030073pubmed: 31491858google scholar: lookup
    11. Persson-Sjodin E, Hernlund E, Pfau T, Haubro Andersen P, Holm Forsström K, Rhodin M. Effect of meloxicam treatment on movement asymmetry in riding horses in training.. PLoS One 2019;14(8):e0221117.
      doi: 10.1371/journal.pone.0221117pubmed: 31408491google scholar: lookup
    12. Ekstrand C, Bondesson U, Giving E, Hedeland M, Ingvast-Larsson C, Jacobsen S, Löfgren M, Moen L, Rhodin M, Saetra T, Ranheim B. Disposition and effect of intra-articularly administered dexamethasone on lipopolysaccharide induced equine synovitis.. Acta Vet Scand 2019 Jun 20;61(1):28.
      doi: 10.1186/s13028-019-0464-2pubmed: 31221173google scholar: lookup
    13. Woodland AN, Van der Saag D, Kimble B, White PJ, Govendir M, Lomax S. Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep.. PLoS One 2019;14(4):e0215842.
      doi: 10.1371/journal.pone.0215842pubmed: 31017959google scholar: lookup
    14. Dunbar ML, Walkowiak KJ, Faustich JS, Rendahl AK, Graham ML. Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Ovis aries).. J Am Assoc Lab Anim Sci 2019 May 1;58(3):339-345.
      doi: 10.30802/AALAS-JAALAS-18-000076pubmed: 30846026google scholar: lookup
    15. Mendoza FJ, Serrano-Rodriguez JM, Perez-Ecija A. Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.. J Vet Intern Med 2019 Mar;33(2):961-967.
      doi: 10.1111/jvim.15433pubmed: 30768821google scholar: lookup
    16. Meléndez DM, Marti S, Pajor EA, Sidhu PK, Gellatly D, Moya D, Janzen ED, Coetzee JF, Schwartzkopf-Genswein KS. Effect of meloxicam and lidocaine administered alone or in combination on indicators of pain and distress during and after knife castration in weaned beef calves.. PLoS One 2018;13(11):e0207289.
      doi: 10.1371/journal.pone.0207289pubmed: 30500846google scholar: lookup
    17. Pugh KA, Reitnauer KJ, Lee RB, Wilkins WL, McDonough JH, Pennington MR, Litvin SR. Plasma Concentration of Meloxicam in Pediatric Rats.. J Am Assoc Lab Anim Sci 2017 Nov 1;56(6):762-767.
      pubmed: 29256371
    18. Banse H, Cribb AE. Comparative efficacy of oral meloxicam and phenylbutazone in 2 experimental pain models in the horse.. Can Vet J 2017 Feb;58(2):157-167.
      pubmed: 28216685
    19. Vivancos M, Barker J, Engbers S, Fischer C, Frederick J, Friedt H, Rybicka JM, Stastny T, Banse H, Cribb AE. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.. Can Vet J 2015 Jul;56(7):730-6.
      pubmed: 26130835
    20. Walliser U, Fenner A, Mohren N, Keefe T, deVries F, Rundfeldt C. Evaluation of the efficacy of meloxicam for post-operative management of pain and inflammation in horses after orthopaedic surgery in a placebo controlled clinical field trial.. BMC Vet Res 2015 May 15;11:113.
      doi: 10.1186/s12917-015-0427-4pubmed: 25976845google scholar: lookup
    21. Bauer C, Frost P, Kirschner S. Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).. J Am Assoc Lab Anim Sci 2014 Sep;53(5):502-11.
      pubmed: 25255073
    22. Kreuder AJ, Coetzee JF, Wulf LW, Schleining JA, KuKanich B, Layman LL, Plummer PJ. Bioavailability and pharmacokinetics of oral meloxicam in llamas.. BMC Vet Res 2012 Jun 21;8:85.
      doi: 10.1186/1746-6148-8-85pubmed: 22720782google scholar: lookup
    23. Yuan Y, Chen XY, Li SM, Wei XY, Yao HM, Zhong DF. Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs.. Acta Pharmacol Sin 2009 Jul;30(7):1060-4.
      doi: 10.1038/aps.2009.73pubmed: 19543299google scholar: lookup
    Subscribe to our newsletter
    Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.